Here, we investigated the role of SOX11 in breast cancer progression after tumour formation using a doxycycline-inducible EF1A promoter to express SOX11 in DCIS.com cells at a level comparable to that observed in clinical DCIS and breast cancer samples. This evidence concerns the gene SOX11 and ductal breast carcinoma in situ.